Ilodon2 mg

Ilodon is an atypical (second-generation) antipsychotic used in the treatment of psychiatric disorders.

Established / FDA-approved use

• Acute treatment of schizophrenia in adults. Ilodon is indicated for the management of the acute symptoms of schizophrenia in adult patients, based on controlled clinical trials.

Uses not established / not approved

• Ilodon is not approved for the treatment of dementia-related psychosis in elderly patients; use in this population carries a boxed warning of increased mortality (see Precautions and Warnings).
• Ilodon is not approved for use in children or adolescents (below 18 years); safety and efficacy have not been established in this age group.

Ilodon should only be used for indications supported by adequate evidence and physician judgment; it should not be used off-label without careful risk-benefit assessment by a qualified physician.

Each tablet contains Iloperidone as the active pharmaceutical ingredient. Iloperidone is available as oral tablets in various strengths (commonly ranging from 1 mg to 12 mg) to allow the gradual dose titration required at treatment initiation.

Ilodon is a second-generation (atypical) antipsychotic agent chemically classified as a benzisoxazole derivative. It is used for the management of schizophrenia and works by modulating dopamine and serotonin neurotransmission in the brain.

A distinguishing feature of Ilodon therapy is the requirement for a slow dose-titration schedule at the start of treatment, primarily to reduce the risk of orthostatic hypotension.

Ilodon belongs to the therapeutic class of atypical (second-generation) antipsychotics.

Mechanism of Action

The precise mechanism of Iloperidone in schizophrenia is not fully known, but its therapeutic effect is thought to be mediated through a combination of antagonism at central dopamine D2 and serotonin 5-HT2A receptors. Iloperidone also has significant affinity for alpha-1 adrenergic receptors, which contributes to its propensity for orthostatic hypotension, and for D3, 5-HT6, and 5-HT7 receptors.

Pharmacokinetics

Iloperidone is well absorbed orally, with food having minimal effect on absorption. It is extensively metabolized in the liver, principally via the CYP2D6 and CYP3A4 enzyme pathways, producing two major active metabolites (P88 and P95). The elimination half-life of Iloperidone is approximately 18 hours in extensive CYP2D6 metabolizers and up to about 33 hours in poor metabolizers. Because metabolism depends heavily on CYP2D6 and CYP3A4, drug interactions and genetic variability in these enzymes significantly affect Iloperidone exposure and QT-prolongation risk.

Ilodon tablets are taken orally, with or without food. Swallow the tablet whole with water; do not crush or chew unless advised by a physician. Take doses at consistent times each day (typically twice daily, morning and evening) to maintain steady drug levels. Do not stop or change the dose without consulting a physician, as re-titration is needed after any significant interruption in therapy.

Clinically Significant Interactions

• Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase Ilodon plasma levels and QT-prolongation risk; the Ilodon dose should be reduced by half.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): similarly increase Ilodon exposure; reduce the Ilodon dose by half.
• Other QT-prolonging drugs (e.g., certain Class IA/III antiarrhythmics, some antibiotics and antipsychotics): concurrent use with Ilodon should be avoided due to additive risk of dangerous QT prolongation and arrhythmia (see Contraindications).
• CNS depressants (e.g., alcohol, sedatives, opioids): may have additive sedative effects when combined with Ilodon.
• Antihypertensive agents: may have additive hypotensive effect with Ilodon, worsening orthostatic hypotension.
• Dopamine agonists (e.g., levodopa): Ilodon may antagonize their effect due to its dopamine-blocking activity.

Common Side Effects

• Dizziness and orthostatic hypotension (most common at treatment initiation/titration)
• Dry mouth
• Fatigue and somnolence
• Tachycardia (reflex, related to orthostatic hypotension)
• Nasal congestion
• Weight gain

Serious but Less Common Side Effects

• QT interval prolongation, with risk of serious arrhythmia in susceptible patients
• Neuroleptic malignant syndrome (rare, potentially fatal)
• Tardive dyskinesia (may be irreversible)
• Metabolic changes: hyperglycemia, dyslipidemia, and weight gain requiring periodic monitoring
• Leukopenia, neutropenia, or agranulocytosis (rare, class effect of antipsychotics)

Pregnancy: Ilodon should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use. Antipsychotic medications, including Ilodon, used during the third trimester have been associated with a risk of extrapyramidal and/or withdrawal symptoms in the neonate following delivery; newborns exposed during the third trimester should be monitored.

Lactation: It is not well established whether Ilodon passes into human breast milk. Breastfeeding while on Ilodon should only be undertaken after consulting a physician, weighing the benefits of breastfeeding against the potential risk to the infant.

Boxed Warnings

• Increased mortality in elderly patients with dementia-related psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs, including Ilodon, are at increased risk of death compared to placebo. Ilodon is not approved for the treatment of dementia-related psychosis.
• QT prolongation: Ilodon causes dose-dependent QT interval prolongation. Slow dose titration at initiation is required, and Ilodon should be avoided in patients with risk factors for QT prolongation or in combination with other QT-prolonging drugs (see Contraindications and Interactions).

Other Precautions

• Orthostatic hypotension: More pronounced with Ilodon than with some other atypical antipsychotics; the gradual dose-titration schedule at initiation is specifically designed to mitigate this risk. Use caution in patients with cardiovascular disease, cerebrovascular disease, or predisposition to hypotension.
• Neuroleptic malignant syndrome (NMS): A rare but potentially fatal reaction; discontinue Ilodon immediately if suspected.
• Tardive dyskinesia: Risk increases with duration of treatment and cumulative dose; use the lowest effective dose for the shortest duration needed.
• Metabolic changes: Monitor for hyperglycemia, dyslipidemia, and weight gain during Ilodon therapy.
• Use with caution in patients with a history of seizures, in hepatic impairment, and in conditions predisposing to electrolyte disturbances (which can worsen QT prolongation).

Overdose with Ilodon may present with exaggeration of known pharmacological effects, including drowsiness, tachycardia, hypotension, and QT interval prolongation which can progress to serious arrhythmia. There is no specific antidote for Ilodon overdose.

If overdose is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Management should take place in a facility capable of cardiac monitoring, and treatment is generally supportive; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly

Ilodon is not approved for dementia-related psychosis in elderly patients due to increased mortality risk (see boxed warning). Use in elderly patients for approved indications should be individualized with careful monitoring for orthostatic hypotension and QT effects.

Renal Impairment

No specific dose adjustment established for mild-to-moderate impairment; use with caution in severe renal impairment as it has not been systematically studied.

Hepatic Impairment

Use with caution; Ilodon has not been systematically studied in patients with severe hepatic impairment.

CYP2D6 Poor Metabolizers

Patients who are known poor CYP2D6 metabolizers require a Ilodon dose reduced to half of the standard dose, due to higher plasma concentrations and increased QT-prolongation risk.

Pediatric Population

Safety and efficacy of Ilodon have not been established in patients under 18 years of age; use in this population is not recommended.

The duration of Ilodon therapy should be individualized by the treating physician based on clinical response, tolerability, and the nature of the underlying condition. Response to Ilodon should be reassessed periodically, and the lowest effective dose should be used for the shortest duration consistent with treatment goals, given the risk of tardive dyskinesia with long-term use. Any discontinuation or dose interruption of more than 3 days requires re-titration from the starting dose. Do not stop Ilodon abruptly without medical advice.

Iloperidone belongs to the atypical (second-generation) antipsychotics, specifically the benzisoxazole derivative class.

Iloperidone exerts its antipsychotic effect primarily through antagonism of central dopamine D2 receptors and serotonin 5-HT2A receptors, with additional activity at D3, 5-HT6, 5-HT7, and alpha-1 adrenergic receptors, the latter contributing to its orthostatic hypotension profile.

C

Ilodon is not approved for use in children or adolescents. Safety and efficacy of Ilodon have not been established in patients below 18 years of age; therefore its use in pediatric patients is not recommended outside of a physician-supervised, evidence-based context.